Infections in Immunocompromised Patients

Staphylococci in Human Disease: Second Edition

Volumn , Issue , 2009, Pages 505-520

  Davidson, Lisa E ^a   Boucher, Helen W ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease and infection; Chronic medical conditions altered immune response to infection; Daptomycin new treatment for drug resistant Gram positive infections; Immunocompromised patients and infections; Multifactorial host defense defect diseases; Solid organ transplant patients and risk factors; Staphylococcal infection in immunocompromised hosts with central venous catheter (CVC) placement; Staphylococcal infections in patients malignancy and organ transplantation; Staphylococci pathogens in triple threat chronic disease patients

Indexed keywords

EID: 84890691224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444308464.ch28     Document Type: Chapter

References (237)

1. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-10.
2. Benfield T, Espersen F, Frimodt-Moller N et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect 2007;13:257-63.
3. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005;11:868-72.
4. Noskin GA, Rubin RJ, Schentag JJ et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005;165:1756-61.
5. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5:9-17.
6. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71.
7. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
8. Breen JD, Karchmer AW. Staphylococcus aureus infections in diabetic patients. Infect Dis Clin North Am 1995;9:11-24.
9. Musher DM, Lamm N, Darouiche RO, Young EJ, Hamill RJ, Landon GC. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine 1994;73:186-208.
10. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003;187:1452-9.
11. Boyce JM. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 1989;3:901-13.
12. Fishbain JT, Lee JC, Nguyen HD et al. Nosocomial transmission of methicillin-resistant Staphylococcus aureus: a blinded study to establish baseline acquisition rates. Infect Control Hosp Epidemiol 2003;24:415-21.
13. Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:309-17.
14. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Communityacquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-86.
15. Cabell CH, Jollis JG, Peterson GE et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002;162:90-4.
16. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S114- S132.
17. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
18. Whitby M, McLaw ML, Berry G. Mortality rates associated with methicillin-resistant and -susceptible Staphylococcus aureus infections. Clin Infect Dis 2003;37:459; author reply 459-60.
19. Fowler VG Jr, Miro JM, Hoen B et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005;293: 3012-21.
20. Miro JM, Anguera I, Cabell CH et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005;41:507-14.
21. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003;45:279-85.
22. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996;23:255-9.
23. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
24. Centers for Disease Control and Prevention. Methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) Among ICU Patients, 1995-2004 Available from http://www.cdc.gov/ ncidod/dhqp/pdf/ar/ICU_RESTrend1995-2004.pdf. Accessed July 31, 2007.
25. Crum NF, Lee RU, Thornton SA et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 2006;119:943-51.
26. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis 2007;31:236-42.
27. Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42:647-56.
28. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillinresistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389-91.
29. Johnson LB, Venugopal AA, Pawlak J, Saravolatz LD. Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease. Infect Control Hosp Epidemiol 2006;27:1057-62.
30. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32.
31. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008;197:1226-34.
32. Kuehnert MJ, Kruszon-Moran D, Hill HA et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9.
33. Squier C, Rihs JD, Risa KJ et al. Staphylococcus aureus rectal carriage and its association with infections in patients in a surgical intensive care unit and a liver transplant unit. Infect Control Hosp Epidemiol 2002;23:495-501.
34. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20.
35. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001;344:11-16.
36. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR. Staphylococcus aureus nasal colonization in patients with cirrhosis:prospective assessment of association with infection. Infect Control Hosp Epidemiol 1998;19:328-32.
37. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001;127:443-50.
38. Mathews WC, Caperna JC, Barber RE et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr 2005;40:155-60.
39. Weinke T, Schiller R, Fehrenbach FJ, Pohle HD. Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1992;11:985-9.
40. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transplant 2003;9:754-9.
41. Wertheim HF, Vos MC, Ott A et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004;364:703-5.
42. Dupeyron C, Campillo SB, Mangeney N, Richardet JP, Leluan G. Carriage of Staphylococcus aureus and of Gram-negative bacilli resistant to third-generation cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired infections. Infect Control Hosp Epidemiol 2001;22:427-32.
43. Chang FY, Singh N, Gayowski T, Drenning SD, Wagener MM, Marino IR. Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation 1998;65:1169-72.
44. Jensen AG, Wachmann CH, Poulsen KB et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999;159:1437-44.
45. Tacconelli E, Tumbarello M, Pittiruti M et al. Central venous catheter-related sepsis in a cohort of 366 hospitalised patients. Eur J Clin Microbiol Infect Dis 1997;16:203-9.
46. Ghanem GA, Boktour M, Warneke C et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 2007;86:54-60.
47. Nicastri E, Petrosillo N, Viale P, Ippolito G. Catheter-related bloodstream infections in HIV-infected patients 1. Ann NY Acad Sci 2001;946:274-90.
48. Senthilkumar A, Kumar S, Sheagren JN. Increased incidence of Staphylococcus aureus bacteremia in hospitalized patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001;33: 1412 -16.
49. Stroud L, Srivastava P, Culver D et al. Nosocomial infections in HIV-infected patients: preliminary results from a multicenter surveillance system (1989-1995). Infect Control Hosp Epidemiol 1997;18:479-85.
50. Petrosillo N, Viale P, Nicastri E et al. Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors 1. Clin Infect Dis 2002;34: 677-85.
51. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343:1703-14.
52. Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol 2007;14:29- 36.
53. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16.
54. Donnelly JP, de Pauw BE. Infections in the immunocompromised host: general principles. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Elsevier, 2005:3421-32.
55. Brinchmann JE, Gaudernack G, Thorsby E, Vartdal F. Staphylococcal exotoxin superantigens induce human immunodeficiency virus type 1 expression in naturally infected CD4??T cells. J Virol 1992;66:5924-8.
56. Goujard C, Wallon C, Rudent A, Boue F, Barre-Sinoussi F, Delfraissy JF. Staphylococcal superantigens activate HIV-1 replication in naturally infected monocytes. Aids 1994;8:1397- 404.
57. Hashimoto K, Shigeta S, Baba M. Superantigen toxic shock syndrome toxin-1 (TSST-1) enhances the replication of HIV-1 in peripheral blood mononuclear cells through selective activation of CD4??T lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:393-9.
58. Juffermans NP, Paxton WA, Dekkers PE et al. Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(?) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood 2000;96:2649-54.
59. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999;341: 1906-12.
60. Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes 2005;54:2904-10.
61. Chu VH, Cabell CH, Benjamin DK Jr et al. Early predictors of in-hospital death in infective endocarditis. Circulation 2004; 109:1745-9.
62. Tamer A, Karabay O, Ekerbicer H. Staphylococcus aureus nasal carriage and associated factors in type 2 diabetic patients. Jpn J Infect Dis 2006;59:10-14.
63. Ahluwalia A, Sood A, Sood A, Lakshmy R, Kapil A, Pandey RM. Nasal colonization with Staphylococcus aureus in patients with diabetes mellitus. Diabet Med 2000;17:487-8.
64. Chandler PT, Chandler SD. Pathogenic carrier rate in diabetes mellitus. Am J Med Sci 1977;273:259-65.
65. Smith JA, O'Connor JJ. Nasal carriage of Staphylococcus aureus in diabetes mellitus. Lancet 1966;ii:776-7.
66. Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate. JAMA 1975;231:1272.
67. Boyko EJ, Lipsky BA, Sandoval R et al. NIDDM and prevalence of nasal Staphylococcus aureus colonization. San Luis Valley Diabetes Study. Diabetes Care 1989;12:189-92.
68. Lipsky BA, Pecoraro RE, Chen MS, Koepsell TD. Factors affecting staphylococcal colonization among NIDDM outpatients. Diabetes Care 1987;10:483-6.
69. Graham PL III, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 2006;144:318-25.
70. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009;41:4-9.
71. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999;16:767-71.
72. Hartemann-Heurtier A, Robert J, Jacqueminet S et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med 2004;21:710-15.
73. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.
74. Roghmann MC, Siddiqui A, Plaisance K, Standiford H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001;47:98-103.
75. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus. An emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-24.
76. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352: 1445-53.
77. Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of Staphylococcus aureus. Infect Dis Clin North Am 2001;15:731-42, vii.
78. Marr KA. Staphylococcus aureus bacteremia in patients undergoing hemodialysis. Semin Dial 2000;13:23-9.
79. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999;55:1081-90.
80. Perazella MA, Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004;17:57-60.
81. Haag-Weber M, Dumann H, Horl WH. Effect of malnutrition and uremia on impaired cellular host defence. Miner Electrolyte Metab 1992;18:174-85.
82. Vychytil A, Lorenz M, Schneider B, Horl WH, Haag-Weber M. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients. J Am Soc Nephrol 1998;9:669-76.
83. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-6.
84. Piraino B, Perlmutter JA, Holley JL, Bernardini J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial Int 1993; 13(suppl 2):S332- S334.
85. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD. Prevalence of colonization with community-associated methicillinresistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 2009;30:4-8.
86. Klevens RM, Tokars JI, Andrus M. Electronic reporting of infections associated with hemodialysis. Nephrol News Issues 2005;19:37-8, 43.
87. Centers for Disease Control and Prevention. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients: United States, 2005. MMWR 2007;56:197-9.
88. Abbott KC, Agodoa LY. Etiology of bacterial septicemia in chronic dialysis patients in the United States. Clin Nephrol 2001;56:124-31.
89. Marr KA, Kong L, Fowler VG et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998;54:1684-9.
90. Nissenson AR, Dylan ML, Griffiths RI et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 2005;46: 301-8.
91. Bernardini J, Holley JL, Johnston JR, Perlmutter JA, Piraino B. An analysis of ten-year trends in infections in adults on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1991;36:29- 34.
92. Leigh DA. Peritoneal infections in patients on long-term peritoneal dialysis before and after human cadaveric renal transplantation. J Clin Pathol 1969;22:539-44.
93. Szeto CC, Leung CB, Chow KM et al. Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in South-East Asia. Clin Microbiol Infect 2005;11:837-9.
94. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252-62.
95. Chapoutot C, Pageaux GP, Perrigault PF et al. Staphylococcus aureus nasal carriage in 104 cirrhotic and control patients. A prospective study. J Hepatol 1999;30:249-53.
96. Campillo B, Richardet JP, Kheo T, Dupeyron C. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002;35:1-10.
97. Thulstrup AM, Sorensen HT, Schonheyder HC, Moller JK, Tage-Jensen U. Population-based study of the risk and shortterm prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000;31:1357-61.
98. Rabinovitz M, Prieto M, Gavaler JS, Van Thiel DH. Bacteriuria in patients with cirrhosis. J Hepatol 1992;16:73-6.
99. Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000;30:256-60.
100. Mukau L, Talamini MA, Sitzmann JV, Burns RC, McGuire ME. Long-term central venous access vs other home therapies: complications in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 1992;16:455- 9.
101. Nguyen MH, Kauffman CA, Goodman RP et al. Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann Intern Med 1999;130:221-5.
102. Frank U, Daschner FD, Schulgen G, Mills J. Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;25:318-20.
103. Melles DC, Pauw E, van den Boogaard L et al. Host-microbe interplay in persistent Staphylococcus aureus nasal carriage in HIV patients. Microbes Infect 2008;10:151-8.
104. Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr 2008;48:567-71.
105. Tumbarello M, de Gaetano DK, Tacconelli E et al. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob Chemother 2002;50:375-82.
106. Senthilkumar A, Kumar S, Sheagren JN. Increased incidence of Staphylococcus aureus bacteremia in hospitalized patients with acquired immunodeficiency syndrome 1. Clin Infect Dis 2001;33:1412-16.
107. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis 2008;8:40.
108. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000;117:1017- 22.
109. Salami AK, Olatunji PO, Oluboyo PO, Akanbi AA, Fawibe EA. Bacterial pneumonia in the AIDS patients. West Afr J Med 2006;25:1-5.
110. Soubani AO, Michelson MK, Karnik A. Pleural fluid findings in patients with the acquired immunodeficiency syndrome: correlation with concomitant pulmonary disease. South Med J 1999;92:400-3.
111. Dicpinigaitis PV, Levy DE, Gnass RD, Bernstein RG. Pneumonia due to Staphylococcus aureus in a patient with AIDS: review of incidence and report of an atypical roentgenographic presentation. South Med J 1995;88:586-90.
112. Tumbarello M, Tacconelli E, Lucia MB, Cauda R, Ortona L. Predictors of Staphylococcus aureus pneumonia associated with human immunodeficiency virus infection. Respir Med 1996;90: 531-7.
113. Smith NP, Nelson MR, Moore D, Gazzard BG. Cerebral abscesses in a patient with AIDS caused by methicillin-resistant Staphylococcus aureus (MRSA). Int J STD AIDS 1997;8:459-60.
114. Gunnarsson G, Friedman LS, Wanke C. Liver abscesses due to Staphylococcus aureus in a patient with AIDS who underwent small bowel biopsy: case report and review. Clin Infect Dis 1994;18:802-4.
115. Grant A, Pitkin AD, Buscombe JR, Corcoran GD, Miller RF. Staphylococcus aureus pericarditis in a patient with AIDS. Genitourin Med 1993;69:324-5.
116. Rivera J, Monteagudo I, Lopez-Longo J, Sanchez-Atrio A. Septic arthritis in patients with acquired immunodeficiency syndrome with human immunodeficiency virus infection. J Rheumatol 1992;19:1960-2.
117. Nelson MR, Daniels D, Dean R, Barton S, Gazzard BG. Staphylococcus aureus psoas abscess in a patient with AIDS. Int J STD AIDS 1992;3:294.
118. Schwartzman WA, Lambertus MW, Kennedy CA, Goetz MB. Staphylococcal pyomyositis in patients infected by the human immunodeficiency virus. Am J Med 1991;90:595-600.
119. Pirofski L, Casadevall A. Mixed staphylococcal and cryptococcal epidural abscess in a patient with AIDS. Rev Infect Dis 1990;12:964-5.
120. Buskila D, Tenenbaum J. Septic bursitis in human immunodeficiency virus infection. J Rheumatol 1989;16:1374-6.
121. Lee NE, Taylor MM, Bancroft E et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005;40:1529-34.
122. Skiest D, Brown K, Hester J et al. Community-onset methicillinresistant Staphylococcus aureus in an urban HIV clinic. HIV Medicine 2006;7:361-8.
123. Gopal AK, Fowler VG Jr, Shah M et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000;18:1110-15.
124. Shah MA, Sanders L, Lanclos K et al. Staphylococcus aureus bacteremia in patients with neutropenia. South Med J 2002;95: 782-4.
125. Salazar R, Sola C, Maroto P et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:27-33.
126. Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant 2007;40:63-70.
127. Blijlevens NM, Donnelly JP, de Pauw BE. Microbiologic consequences of new approaches to managing hematologic malignancies. Rev Clin Exp Hematol 2005;9:E2.
128. Freifeld AG, Segal BH. Prevention and treatment of cancerrelated infection. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/ infections.pdf. Accessed July 31, 2007.
129. Choi G, van den Borne MP, Visser CE, Kersten MJ, Kater AP. Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. Ann Hematol 2008;87:771-2.
130. Wisplinghoff H, Cornely OA, Moser S et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol 2003;24:905-11.
131. Seifert H, Cornely O, Seggewiss K et al. Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis. J Clin Microbiol 2003;41:118-23.
132. Morris PG, Hassan T, McNamara M et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia: a cause for concern. Support Care Cancer 2008;16:1085-8.
133. Gonzalez-Barca E, Carratala J, Mykietiuk A, Fernandez-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 2001;20:117-19.
134. Miller LW, Naftel DC, Bourge RC et al. Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994;13: 381-92.
135. Montoya JG, Giraldo LF, Efron B et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001;33:629-40.
136. Adeyemi OA, Qi C, Zembower TR et al. Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation. J Clin Microbiol 2008;46: 2809-13.
137. Bert F, Bellier C, Lassel L et al. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transplant 2005;11:1093-9.
138. Woeste G, Zapletal C, Wullstein C, Golling M, Bechstein WO. Influence of methicillin-resistant Staphylococcus aureus carrier status in liver transplant recipients. Transplant Proc 2005;37: 1710-12.
139. Schneider CR, Buell JF, Gearhart M et al. Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study. Transplant Proc 2005;37:1243-4.
140. Singh N, Paterson DL, Chang FY et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant Grampositive coccus among liver transplant recipients. Clin Infect Dis 2000;30:322-7.
141. Santoro-Lopes G, de Gouvea EF, Monteiro RC et al. Colonization with methicillin-resistant Staphylococcus aureus after liver transplantation. Liver Transplant 2005;11:203-9.
142. Singh N, Gayowski T, Wagener MM, Marino IR. Bloodstream infections in liver transplant recipients receiving tacrolimus. Clin Transplant 1997;11:275-81.
143. Torre-Cisneros J, Herrero C, Canas E, Reguera JM, De La Mata M, Gomez-Bravo MA. High mortality related with Staphylococcus aureus bacteremia after liver transplantation. Eur J Clin Microbiol Infect Dis 2002;21:385-8.
144. Hashimoto M, Sugawara Y, Tamura S et al. Impact of new methicillin-resistant Staphylococcus aureus carriage postoperatively after living donor liver transplantation. Transplant Proc 2007;39:3271-5.
145. Singh N, Wannstedt C, Keyes L et al. Hepatic iron content and the risk of Staphylococcus aureus bacteremia in liver transplant recipients. Prog Transplant 2007;17:332-6.
146. Monkowski DH, Axelrod P, Fekete T, Hollander T, Furukawa S, Samuel R. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis 2007;9:114-20.
147. Springer WE, Wasler A, Radovancevic B et al. Retrospective analysis of infection in patients undergoing support with left ventricular assist systems. ASAIO J 1996;42:M763-M765.
148. Schmid C, Schneider M, Etz C, Scheld HH. Heart transplantation in a patient with a left ventricular assist device and methicillin-resistant Staphylococcus aureus infection. Ann Thorac Surg 2004;78:1820-1.
149. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med 1998;339:1522-33.
150. Baldwin RT, Radovancevic B, Sweeney MS, Duncan JM, Frazier OH. Bacterial mediastinitis after heart transplantation. J Heart Lung Transplant 1992;11:545-9.
151. Stolf NA, Fiorelli AI, Bacal F et al. Mediastinitis after cardiac transplantation. Arq Bras Cardiol 2000;74:419-30.
152. Senechal M, LePrince P, Tezenas du MS et al. Bacterial mediastinitis after heart transplantation: clinical presentation, risk factors and treatment. J Heart Lung Transplant 2004;23:165- 70.
153. Dodds Ashley ES, Carroll DN, Engemann JJ et al. Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;38:1555-60.
154. Caballero F, Lopez-Navidad A, Perea M, Cabrer C, Guirado L, Sola R. Successful liver and kidney transplantation from cadaveric donors with left-sided bacterial endocarditis. Am J Transplant 2005;5:781-7.
155. Nassar GM, Ayus JC. Infectious complications of old nonfunctioning arteriovenous grafts in renal transplant recipients: a case series. Am J Kidney Dis 2002;40:832-6.
156. D'Cunha PT, Davenport DS, Fisher KA. Successful treatment of Staphylococcus aureus bacterial endocarditis in a renal transplant recipient. Transplant Infect Dis 2003;5:144-6.
157. Bishara J, Robenshtok E, Weinberger M, Yeshurun M, Sagie A, Pitlik S. Infective endocarditis in renal transplant recipients. Transplant Infect Dis 1999;1:138-43.
158. Paterson DL, Dominguez EA, Chang FY, Snydman DR, Singh N. Infective endocarditis in solid organ transplant recipients. Clin Infect Dis 1998;26:689-94.
159. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transplant 2003;9:451-62.
160. Obed A, Schnitzbauer AA, Bein T, Lehn N, Linde HJ, Schlitt HJ. Fatal pneumonia caused by Panton-Valentine leucocidinpositive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation 2006;81:121-4.
161. Villavicencio RT, Wall MJ Jr. The pathogenesis of Staphylococcus aureus in the trauma patient and potential future therapies 1. Am J Surg 1996;172:291-6.
162. Croce MA, Fabian TC, Stewart RM et al. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma 1993;35:303-9.
163. Edwards-Jones V, Greenwood JE. What's new in burn microbiology? James Laing Memorial Prize Essay 2000. Burns 2003; 29:15-24.
164. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med 1999;27:798-801.
165. Vindenes H, Bjerknes R. The frequency of bacteremia and fungemia following wound cleaning and excision in patients with large burns. J Trauma 1993;35:742-9.
166. Bauer GJ, Yurt RW. Burns. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Elsevier, 2005:3547-52.
167. Edwards-Jones V, Dawson MM, Childs C. A survey into toxic shock syndrome (TSS) in UK burns units. Burns 2000;26:323-33.
168. Kimura A, Mochizuki T, Nishizawa K, Mashiko K, Yamamoto Y, Otsuka T. Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998;45:383-7.
169. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
170. Agusti C, Rano A, Filella X et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488-98.
171. Koka VK, Potti A. Spinal epidural abscess after corticosteroid injections 1. South Med J 2002;95:772-4.
172. Konno O, Hirano T, Katsuyama K, Oka K, Matsuno N, Nagao T. Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment. Transpl Immunol 2007;17:187-92.
173. Fukushima H, Hirano T, Oka K. Staphylococcus aureussuperantigen decreases FKBP51 mRNA expression and cellresponse to suppressive efficacy of a glucocorticoid in human peripheral blood mononuclear cells: possible implication of mitogen-activated protein kinase pathways. Eur J Pharmacol 2007;570:222-8.
174. Bassetti S, Wasmer S, Hasler P et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment 1. J Rheumatol 2005;32:2125-9.
175. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept orconventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-61.
176. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
177. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
178. Sweet DD, Isac G, Morrison B, Fenwick J, Dhingra V. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate. CJEM 2007;9:40-2.
179. Oda S, Fujinaga H, Takahashi K. Infectious myositis involving the piriformis in a patient with rheumatoid arthritis. Mod Rheumatol 2006;16:260- 3.
180. Fitch PG, Cron RQ. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha. J Rheumatol 2006;33:825-7.
181. Fowler VG Jr, Li J, Corey GR et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997;30:1072-8.
182. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
183. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32:1249-72.
184. Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003;163:2066-72.
185. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9.
186. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984;144:541-5.
187. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115: 457-69.
188. Kamel NS, Banks MC, Dosik A, Ursea D, Yarilina AA, Posnett DN. Lack of muco-cutaneous signs of toxic shock syndrome when T cells are absent: S. aureus shock in immunodeficient adults with multiple myeloma. Clin Exp Immunol 2002;128:131-9.
189. Goldberg NS, Ahmed T, Robinson B, Ascensao J, Horowitz H. Staphylococcal scalded skin syndrome mimicking acute graftvs-host disease in a bone marrow transplant recipient. Arch Dermatol 1989;125:85-7.
190. Huseyin TS, Maynard JP, Leach RD. Toxic shock syndrome in a patient with breast cancer and systemic lupus erythematosus. Eur J Surg Oncol 2001;27:330-1.
191. Takeuchi F, Watanabe S, Baba T et al. Whole-genome sequencing of Staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. J Bacteriol 2005;187:7292-308.
192. Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-6.
193. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
194. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005;55:436-44.
195. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:431-9.
196. Cometta A, Kern WV, De Bock R et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382-9.
197. Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebocontrolled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000;45:843-9.
198. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.
199. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7.
200. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR 2002;51:565-7.
201. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001;32:108-15.
202. Bert F, Clarissou J, Durand F et al. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 2003;41:5147-52.
203. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597- 607.
204. Odakowska-Jedynak U, Paczek L, Krawczyk M et al. Resistance of Gram-positive pathogens to antibiotics is a therapeutic challenge after liver transplantation: clinical experience in one center with linezolid. Transplant Proc 2003;35:2304-6.
205. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005;56:923-9.
206. Smith PF, Birmingham MC, Noskin GA et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003;14:795-801.
207. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;26:442-8.
208. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.
209. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Linezolid Diabetic Foot Infections Study Group. Clin Infect Dis 2004;38:17-24.
210. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006;25:562-4.
211. Information for Healthcare Professionals: Linezolid (marketed as Zyvox). Center for Drug Evaluation and Research, US Food and Drug Administration, March 16, 2007. http://www.fda.gov/ cder/drug/infopage/linezolid/default.htm. Accessed July 31, 2007.
212. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-5.
213. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycinresistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60.
214. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6.
215. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003;37:933-8.
216. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a metaanalysis. Clin Infect Dis 2003;37:1629-38.
217. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003;75:194 -8.
218. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003;4:CD003340.
219. Wertheim HF, Vos MC, Ott A et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004;140: 419-25.
220. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev 2004;4:CD004679.
221. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002;39:337-41.
222. Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. Am J Infect Control 2006;34:476-83.
223. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006;27:185-7.
224. Simor AE, Phillips E, McGeer A et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007;44:178-85.
225. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002;23:759-69.
226. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362-86.
227. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol 2006;27:122-6.
228. Raad I, Hachem R, Tcholakian RK, Sherertz R. Efficacy of minocycline and EDTA lock solution in preventing catheterrelated bacteremia, septic phlebitis, and endocarditis in rabbits. Antimicrob Agents Chemother 2002 Feb;46:327-32.
229. Carratala J, Niubo J, Fernandez-Sevilla A et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of Gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999;43:2200-4.
230. Chatzinikolaou I, Zipf TF, Hanna H et al. Minocycline- ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis 2003;36:116-19.
231. Kim SH, Kang CI, Kim HB et al. Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003;24: 897-904.
232. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006;43:474-84.
233. Chu VH, Crosslin DR, Friedman JY et al. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med 2005;118:1416.
234. Engemann JJ, Friedman JY, Reed SD et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005;26:534-9.
235. Weems JJ Jr, Steinberg JP, Filler S et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006;50:2751-5.
236. Domanski PJ, Patel PR, Bayer AS et al. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005;73: 5229-32.
237. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-6.